Pancreatic NET with carcinoid syndrome – not as common as you think

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,917 other subscribers.

Why do I need to write about this?

I’ve been watching confusion surrounding symptomatic pancreatic NETs for years and it never ceases to amaze me that people automatically think “carcinoid syndrome”.  Despite the fact that pancreatic NETs were never included in the category of “carcinoid tumours”; and despite the fact that there are at least 6 or 7 known pancreatic NET hormonal syndromes, this myth persists.  Don’t misunderstand me though, a serotonin secreting pancreatic NET is possible, it’s just not nearly as common as it’s made out in patient groups and on some websites. It’s a highly unusual scenario. 

Why is this a problem?  A mixture of issues, including but not unlimited to; poor moderation in patient groups, websites out of date, doctors out of date, even the names of patient advocacy groups cause such confusion.   

Many pancreatic NET patients claim carcinoid syndrome as they have diarrhea.  But if you look at the symptoms of non-functional and functional pancreatic NETs, in addition to secondary issues, diarrhea comes up several times including but not limited to; non-functional pancreatic NET, and functional pancreatic NETs such as Gastrinoma, VIPoma and Somatostatinoma.  Add confusion I see in patient groups between diarrhea and steatorrheaFlushing already has several secondary causes outside of carcinoid syndrome – read more by clicking here

Incidence of serotonin secretion in pancreatic neuroendocrine tumours

I wanted to confirm how uncommon this scenario was and found this study from some of the world’s most respected NET experts who work in one of the world’s most respected NET centres of excellence.  This is backed up by another document referred below (Reference 1).

It’s known that serotonin can be elevated but not sufficiently to cause symptoms or carcinoid syndrome, which is true of many hormonal issues with most NETs.  It’s also known that many cases of carcinoid syndrome do not manifest until there are liver metastases (or less common scenarios as described below).

According to Reference 1, Carcinoid syndrome occurs when biologically active amines and peptides enter the systemic circulation escaping the first-pass metabolism of the liver. Normally, these bioactive products are inactivated by the liver. However, in cases of neuroendocrine tumours with liver metastasis, either these bioactive products are directly released into the systemic circulation, or they escape inactivation due to deranged liver function.  Less commonly, carcinoid syndrome can occur without liver metastasis in conditions like a primary gut tumour with extensive retroperitoneal nodal metastases, a bronchial or ovarian NET, where it’s possible for bioactive amines to be released directly into the systemic circulation. 

According to Reference 2 below, elevated serotonin is possible in pancreatic NETs (7.8%) but only 0.8% were also diagnosed with carcinoid syndrome.  

Further Reading

  1. Biochemical Testing in Neuroendocrine Tumors – Endocrinol Metab Clin North Am. 2017 Sep; 46(3): 669–677. Published online 2017 Jun 12. doi: 10.1016/j.ecl.2017.04.004 Vidya Aluri, MD, MS and Joseph S. Dillon, MB, BCh
  2. Incidence and prognostic value of serotonin secretion in pancreatic neuroendocrine tumours. Wouter T. ZandeeRoxanne C. van AdrichemKimberly KampRichard A. FeeldersMarie-Louise F. van VelthuysenWouter W. de Herder First published: 02 May 2017
Read more about hormonal syndromes by clicking on this picture


I am not a doctor or any form of medical professional, practitioner or counsellor. None of the information on my website, or linked to my website(s), or conveyed by me on any social media or presentation, should be interpreted as medical advice given or advised by me. 

Neither should any post or comment made by a follower or member of my private group be assumed to be medical advice, even if that person is a healthcare professional.   

Please also note that mention of a clinical service, trial/study or therapy does not constitute an endorsement of that service, trial/study or therapy by Ronny Allan, the information is provided for education and awareness purposes and/or related to Ronny Allan’s own patient experience. This element of the disclaimer includes any complementary medicine, non-prescription over the counter drugs and supplements such as vitamins and minerals.

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,917 other subscribers.

Thanks for reading.


I’m also active on Facebook. Like this page.
I’m also active on this Facebook page. Follow this page.
Also like this awareness page on Facebook. 

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


Summary of May 2023 on RonnyAllan.NET

Summary May produced the best statistics in 2023, mainly due to your support for my blog post on Maria Menounos whose announcement headlined as “Pancreatic

Read More »

Getting back in the saddle

Those who follow my Facebook page Ronny Allan may remember my cycling faux pas in April causing me to bruise or fracture a rib (here

Read More »

Clinical Trial: Phase 1/2a Study of 23ME-00610 in Patients With Advanced Solid Malignancies (incl Neuroendocrine Neoplasms)

Who are 23andMe? I personally had not heard of 23andMe but many people in North America might have.  When you first look at what they

Read More »

A spotlight on Chromogranin A

What is Chromogranin A? Chromogranin A (CgA) is an acidic protein released along with catecholamines from chromaffin cells and nerve terminals. This statement alone might

Read More »

Neuroendocrine Cancer: Catch them early, not late!

Diagnosing Neuroendocrine Neoplasms (NENs). It’s no secret that Neuroendocrine Neoplasms (NENs) can be difficult to diagnose, particularly well differentiated slow growing types (NETs) which can

Read More »

A spotlight on Rectal Neuroendocrine Neoplasms

What are Rectal NENs Rectal Neuroendocrine Neoplasms (NENs) (rNENs) account for approximately 1-2% of all primary cancers in the rectum.  The other main cancer types

Read More »
Clinical Trial

Clinical Trial: Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3) (Beta plus)

A new clinical trial post. What is Terbium-161 (161Tb-DOTA-LM3) (Beta plus). Terbium-161 is a radioactive substance.  DOTA-LM3 is a novel somatostatin antagonist targeted using somatostatin

Read More »

Repeat after me: Maria Menounos has Neuroendocrine Cancer

Like many people from outside USA, I don’t really know anything about Maria Menounos.  For those in the same boat, let me confirm she is

Read More »

Summary of April 2023 on RonnyAllan.NET

Summary of RonnyAllan.NET website activity in April 2023 The top 10 most read posts in April are included below as the main product of this summary

Read More »
Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 19,917 other subscribers.

I love comments - feel free!

%d bloggers like this: